Treeline Biosciences announced plans to enter public markets through an all-stock reverse merger with Standard BioTools, combining precision oncology capabilities with Treeline’s oncology drug-development portfolio. The merged company will operate under the Treeline Biosciences name and trade on Nasdaq under the TRLN ticker. Standard BioTools said it does not plan to continue parts of its mass cytometry or microfluidics businesses and is exploring options such as divestitures to maximize shareholder value. Deal terms point to a cash-backed runway into 2029, positioning the combined company to advance pipeline programs in oncology where investors typically demand credible translational and clinical progress. Key takeaway: Treeline is converting substantial private funding into a public listing to support long-horizon development and improve access to capital.